What PT-141 is
PT-141 is the research name for bremelanotide, a synthetic peptide that acts on melanocortin receptors in the brain. It came out of research on Melanotan II.
Bremelanotide is FDA-approved under the brand name Vyleesi, as a prefilled autoinjector. Vials sold online as "PT-141" are not Vyleesi and have not been evaluated by FDA.
As-needed autoinjector. Approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not approved for men or for erectile dysfunction.
Regulatory status in 2026
Bremelanotide is approved only as Vyleesi, for one specific use. Everything else, including men's use and gray-market vials, is off-label or unapproved.
A nasal form is tested for erectile dysfunction. Development stops, in part over blood pressure increases.
FDA approves Vyleesi for HSDD in premenopausal women.
Vyleesi remains the only approved bremelanotide product. "PT-141" vials sold as research chemicals are not legal for human use.
Regulatory status can change. Check the sources linked at the bottom of this page before relying on anything here.
What's proven vs. what's claimed
Bremelanotide has randomized trial data for its approved use. Most online claims go well beyond it.
Increases sexual desire in premenopausal women with HSDD.
Shown in two randomized trials. Improvements over placebo were modest.
Strong human evidenceTreats erectile dysfunction in men.
Tested earlier in a nasal form. Development stopped. Not approved.
Insufficient dataGray-market PT-141 is the same as Vyleesi.
Not evaluated by FDA for quality, strength, or purity.
Insufficient dataStorage and stability
This is the commonly cited label guidance for Vyleesi. Gray-market vials have no validated storage data, so general peptide handling applies to them.
Vyleesi autoinjector
- Store at or below 77°F (25°C).
- Do not freeze.
- Protect from light.
Gray-market vials
- Keep refrigerated. Do not freeze.
- Protect from light. Clear glass lets it through.
- Opened multi-dose bacteriostatic water is typically discarded 28 days after first puncture.
- Log the mix date so you know the vial's age at a glance.
Light exposure is easy to overlook in a fridge door that opens dozens of times a day. VIALTIGHT is building stackable cases that block light from every side. See vialtight.com for updates.
Safety flags
Blood pressure rises after each dose. The label describes a temporary increase in blood pressure and decrease in heart rate. Not recommended for people with uncontrolled high blood pressure or heart disease.
Nausea is common. Nausea was the most common side effect in trials. Flushing and headache were also common.
Skin darkening. Darkening of the skin, gums, or face has been reported, especially with frequent use.
Drug interaction. Bremelanotide can lower the level of oral naltrexone in the blood.
FAQ
Is PT-141 the same as Vyleesi?
Same molecule. Vyleesi is the FDA-approved, quality-controlled product. Gray-market PT-141 is not.
Is it approved for men?
No. Vyleesi is approved only for premenopausal women with acquired, generalized HSDD.
Does VialTracker tell me what to take?
No. VialTracker organizes the information you enter and runs the math. It does not recommend doses, products, or protocols.